Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (Feb 2017)

Posted by Matt Breese on Feb 14, 2017

Find me on:

According to our recent payer coverage analysis for CF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access by channel shows that health exchange and medicare formularies are more restrictive than commercial formularies. While these channels experienced a slight percentage increase in overall restricted lives, payer coverage remained relatively stable over the past quarter. The analysis below shows the prevalence of PAs in the CF market.

mmit-reality-check-cf-q12017.png

Source: MMIT data as of Q1 2017

Trends: Over recent years, the CF landscape received an injection of new treatments that increased the utilization of specialty pharmacy networks. This theme is shared by other similar highly managed disease areas that require more attention to suffering patients. Organizations like the Cystic Fibrosis Foundation provide patients and prescribers with well-needed resources that create a strong support network.

To read the full Reality Check on cystic fibrosis with key findings on clinical characteristics, CF drug market access and payer coverage, please click on the thumbnail below: 

reality-check-thumbnail-v1-1.png

Topics: Specialty, Market Access, Branding & Marketing